Anti-tumor efficacy of a therapeutic peptide based on thermo-responsive elastin-like polypeptide in combination with gemcitabine

Cancer Letters

Volumn 348, Issue 1-2, 2014, Pages 177-184

  Ryu, Jung Su ^a   Raucher, Drazen ^a  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

Anticancer drug delivery; Elastin like polypeptide; Hyperthermia; P21; Thermally targeting

Indexed keywords

CELL PENETRATING PEPTIDE; CYCLIN DEPENDENT KINASE INHIBITOR 1; ELASTIN; ELASTIN LIKE POLYPEPTIDE; GEMCITABINE; POLYPEPTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG EFFICACY; DRUG TARGETING; DRUG TRANSPORT; FEASIBILITY STUDY; FEMALE; HEAT SENSITIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL;

ANTICANCER DRUG DELIVERY; ELASTIN-LIKE POLYPEPTIDE; HYPERTHERMIA; P21; THERMALLY TARGETING;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL-PENETRATING PEPTIDES; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ELASTIN; FEASIBILITY STUDIES; FEMALE; HUMANS; HYPOTHERMIA, INDUCED; MICE; MICE, NUDE; PANCREATIC NEOPLASMS; PHOSPHORYLATION; RECOMBINANT FUSION PROTEINS; RETINOBLASTOMA PROTEIN; S PHASE CELL CYCLE CHECKPOINTS; TIME FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84900508774     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.03.021     Document Type: Article

References (28)

1. Floss D.M., Schallau K., Rose-John S., Conrad U., Scheller J. Elastin-like polypeptides revolutionize recombinant protein expression and their biomedical application. Trends Biotechnol 2010, 28:37-45.
2. Massodi I., Bidwell G.L., Davis A., Tausend A., Credit K., Flessner M., Raucher D. Inhibition of ovarian cancer cell metastasis by a fusion polypeptide Tat-ELP. Clin Exp Metast 2009, 26:251-260.
3. Raucher D., Chilkoti A. Enhanced uptake of a thermally responsive polypeptide by tumor cells in response to its hyperthermia-mediated phase transition. Cancer Res 2001, 61:7163-7170.
4. Chilkoti A., Dreher M.R., Meyer D.E., Raucher D. Targeted drug delivery by thermally responsive polymers. Adv Drug Deliv Rev 2002, 54:613-630.
5. Dreher M.R., Raucher D., Balu N., Michael Colvin O., Ludeman S.M., Chilkoti A. Evaluation of an elastin-like polypeptide-doxorubicin conjugate for cancer therapy. J Control Release 2003, 91:31-43.
6. Bidwell G.L., Perkins E., Raucher D. A thermally targeted c-Myc inhibitory polypeptide inhibits breast tumor growth. Cancer Lett 2012.
7. Massodi I., Moktan S., Rawat A., Bidwell G.L., Raucher D. Inhibition of ovarian cancer cell proliferation by a cell cycle inhibitory peptide fused to a thermally responsive polypeptide carrier. Int J Cancer 2010, 126:533-544.
8. Moktan S., Perkins E., Kratz F., Raucher D. Thermal targeting of an acid-sensitive doxorubicin conjugate of elastin-like polypeptide enhances the therapeutic efficacy compared to the parent compound in vivo. Mol Cancer Ther 2012.
9. Meyer D.E., Kong G.A., Dewhirst M.W., Zalutsky M.R., Chilkoti A. Targeting a genetically engineered elastin-like polypeptide to solid tumors by local hyperthermia. Cancer Res 2001, 61:1548-1554.
10. Bidwell G.L., Fokt I., Priebe W., Raucher D. Development of elastin-like polypeptide for thermally targeted delivery of doxorubicin. Biochem Pharmacol 2007, 73:620-631.
11. Bidwell G.L., Davis A.N., Fokt I., Priebe W., Raucher D. A thermally targeted elastin-like polypeptide-doxorubicin conjugate overcomes drug resistance. Invest New Drugs 2007, 25:313-326.
12. Bidwell G.L., Perkins E., Hughes J., Khan M., James J.R., Raucher D. Thermally targeted delivery of a c-Myc inhibitory polypeptide inhibits tumor progression and extends survival in a rat glioma model. PLoS ONE 2013, 8:e55104.
13. Bidwell G.L., Raucher D. Application of thermally responsive polypeptides directed against c-Myc transcriptional function for cancer therapy. Mol Cancer Ther 2005, 4:1076-1085.
14. Siegel R., Naishadham D., Jemal A. Cancer statistics. CA Cancer J Clin 2012, 62(2012):10-29.
15. Humbert M., Casteran N., Letard S., Hanssens K., Iovanna J., Finetti P., Bertucci F., Bader T., Mansfield C.D., Moussy A., Hermine O., Dubreuil P. Masitinib combined with standard gemcitabine chemotherapy: in vitro and in vivo studies in human pancreatic tumour cell lines and ectopic mouse model. PLoS ONE 2010, 5:e9430.
16. Bidwell G.L., Whittom A.A., Thomas E., Lyons D., Hebert M.D., Raucher D. A thermally targeted peptide inhibitor of symmetrical dimethylation inhibits cancer-cell proliferation. Peptides 2010, 31:834-841.
17. Butz J., Wickstrom E., Edwards J. Characterization of mutations and loss of heterozygosity of p53 and K-ras2 in pancreatic cancer cell lines by immobilized polymerase chain reaction. BMC Biotechnol 2003, 3:11.
18. Anirban Maitra R.H.H. Pancreatic cancer. Annu. Rev. Pathol. 2008, 3:157-188.
19. Redston M.S., Caldas C., Seymour A.B., Hruban R.H., da Costa L., Yeo C.J., Kern S.E. P53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res 1994, 54:3025-3033.
20. Gartel A.L., Tyner A.L. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 2002, 1:639-649.
21. Mattock H., Lane D.P., Warbrick E. Inhibition of cell proliferation by the PCNA-binding region of p21 expressed as a GFP miniprotein. Exp Cell Res 2001, 265:234-241.
22. Bidwell G.L., Davis A.N., Raucher D. Targeting a c-Myc inhibitory polypeptide to specific intracellular compartments using cell penetrating peptides. J Control Release 2009, 135:2-10.
23. Ogryzko V.V., Wong P., Howard B.H. WAF1 retards S-phase progression primarily by inhibition of cyclin-dependent kinases. Mol Cell Biol 1997, 17:4877-4882.
24. Mikecin A.M., Walker L.R., Kuna M., Raucher D. Thermally targeted p21 peptide enhances bortezomib cytotoxicity in androgen-independent prostate cancer cell lines. Anticancer Drugs 2013.
25. Cayrol C., Knibiehler M., Ducommun B. P21 binding to PCNA causes G1 and G2 cell cycle arrest in p53-deficient cells. Oncogene 1998, 16:311-320.
26. Wiman K.G. The retinoblastoma gene: role in cell cycle control and cell differentiation. Faseb J 1993, 7:841-845.
27. Bartek J., Bartkova J., Lukas J. The retinoblastoma protein pathway in cell cycle control and cancer. Exp Cell Res 1997, 237:1-6.
28. Shi S., Yao W., Xu J., Long J., Liu C., Yu X. Combinational therapy: new hope for pancreatic cancer?. Cancer Lett 2012, 317:127-135.